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age group (< 18, 18–34, 35+), race, ethnicity, number of high-risk diagnosis codes, 
and zip codes. High-risk diagnoses—including prior history of preterm delivery, 
insulin-dependent diabetes, hypertension, multiple gestations, and incompetent 
cervix—are known predictors of low birth weight and premature delivery. Results: 
Thirty-one participants at high-risk for premature delivery received cell phones and 
text-messaging services. Twenty-six mothers (84%) successfully delivered babies to 
term (< 31 days from expected delivery date). Babies born in the IG had higher birth 
weights than those born in the CG (mean, 38.71g), lower rates of low birth weight 
babies (-0.12%) and very low birth weight babies (-0.06%), and delivered almost a 
full week later (mean, 0.96 wk). Participants reported high program-satisfaction 
rates. ConClusions: Members at high risk for preterm delivery participating in 
Moms2B had superior pregnancy outcomes compared to nonparticipants; program 
satisfaction was favorable.
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objeCtives: To apply value of information analysis (VoI) to a cost-effectiveness 
model of a Levonorgestrel intrauterine system LNG-IUS 13.5mg (total content) in 
order to identify parameters worth investigating to reduce remaining uncertainty 
around the reimbursement decision. LNG-IUS 13.5mg is a novel low-dose hormonal 
intrauterine contraceptive system for up to 3 years use and was shown to be cost-
effective over this horizon vs. commonly used short-acting contraceptive methods 
in women aged 20-29. Methods: VoI analyses were performed using an exist-
ing US cost-effectiveness model with LNG-IUS 13.5mg. Expected Value of Perfect 
Information (EVPI) and the parameter EVPIs (EVPPI) for the following groups were 
estimated: probability of failure (unintended pregnancy (UP)); probability of discon-
tinuation during year 1 and subsequent years; and follow-up consultation costs. 
Individual EVPPIs were calculated for probability of failure of injectable contracep-
tives and LNG-IUS 13.5mg and first year discontinuation probability of LNG-IUS 
13.5mg. EVP(P)I were calculated using different willingness to pay (WTP) values for 
an UP and extrapolated to population values. Results: The estimated EVPI was 
$69, $62 and $40 at WTP of $300, $400 and $700 per UP, respectively. EVPPI analysis 
suggested that probabilities of failure and first year discontinuation were the most 
influential, accounting for the majority of uncertainty of the reimbursement deci-
sion. Population EVPI estimates suggested that further research in this area was 
potentially worthwhile. ConClusions: Comparative effectiveness research focus-
ing on the failure rate of injectable contraceptives and the first year discontinuation 
rate of LNG-IUS 13.5mg is potentially worthwhile. Expected value of sample informa-
tion will have to be compared to the actual costs of such research.
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objeCtives: The paucity of pediatric information available on drug labels has-
tened calls for regulatory intervention aimed at providing clinicians with improved 
information to treat pediatric populations, especially neonates. This study exam-
ined how neonatal drug data is presented on labels for approved drugs over the 
past 30 years. Methods: This study included review of publicly available data 
retrieved from the FDA website Drugs@FDA. Three sections of the FDA approved 
label were analyzed for mention of neonates; “Indication and Usage”, “Dosage and 
Administration” and “Pediatric Use”. “Neonates” were defined as infants age 0-28 
days and/or specifically cited as “neonates” or “newborns”. This analysis did not 
include label information pertinent to in utero exposure to drug. Descriptive sta-
tistics were performed and the pharmaceutical active ingredient was the unit of 
analysis. Results: The study included all NDA/BLA approvals by the FDA between 
January 1, 1980 and December 31, 2012 and available on the Drugs@FDA website 
(n= 676). Eleven (1.6%) labels included neonate information in the Indications and 
Usage section, 33 (4.9%) in the Dosage and Administration section and 62 (9.2%) 
in the Pediatric Use section. References to neonates occurred in two sections on 2 
labels (0.3%) and in all three sections on 5 labels (0.7%). Statements that the drug 
was not studied and/or not recommended in neonates were most often found in the 
Pediatric Use section (528, 78%), but also noted in the Dosage and Administration 
section (22, 3.3%) and the Indications and Usage section (9, 1.3%). ConClusions: 
This study demonstrates that data necessary to determine the appropriateness 
of medications in neonates is difficult to find, even when available to clinicians. 
As regulators consider how to improve the quantity and quality of neonatal drug 
data, consideration should be given to standardizing neonatal information on drug 
labels, thereby ensuring that regulatory efforts to incentivize pediatric research 
are optimized.
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objeCtives: Orofacial clefts (OFC) are among the most common birth defects and 
often require hospitalizations during early childhood. We assessed health care 
utilization and costs for children during 2010. Methods: Data were extracted 
from the 2006-2010 MarketScan® Commercial claims databases to identify children 
with ≥ 2 outpatient claims or ≥ 1 inpatient claim for OFC during those five years 
to maximize case ascertainment. Health care utilization and costs during 2010 
3) Brief COPE Scale (higher scores = better coping); 4) Acculturative Stress (ASSIS) 
(higher scores = higher stress) [For international students only] and; 5) demographic 
information. Results: The mean age of the 19 participants was 28.9 years ± 4.6. A 
majority of the respondents were Asian (47.4%), female (73.7%), enrolled in the PhD 
program (73.7%), single (52.6%), international students (57.9%) and lived with family 
(47.4%). Mean PCS and MCS were 49.97 ± 9.3 and 49.97 ± 8.22, respectively, indicating 
that both the physical health and mental health summary scores were comparable 
to the general population. Overall, participants reported low stress (GSI-R) levels 
(mean= 56.53 ± 20.3; range 21 – 147)) and engaged in mid-range levels of coping 
mechanisms to deal with stress (mean= 71.42 ± 7.1; range 28 – 140). Among inter-
national students, acculturative stress levels (mean= 51.10 ± 27.9; range 36 – 180) 
were low. ConClusions: There is a paucity of quantitative data for perceived stress 
among graduate students. The results from this pilot study will be used to imple-
ment a future survey among a larger and more diverse sample of graduate students.
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objeCtives: The purpose of this paper is to propose a simple and efficient approach 
for analyzing multivariate longitudinal data (MLD), such as longitudinal health-
related quality of life (HRQoL) assessments in observational studies. This will be 
accomplished using the combination of two popular statistical methods for causal 
inference and multivariate data, namely the inverse probability-weighted (IPW) esti-
mator and principal component analysis (PCA). Methods: Multivariate outcomes 
at each time point will be converted to the first principal component score (FPCS) for 
each subject. Then all FPCS will be composited into a numerical observation using 
the area under a curve (AUC). The IPW estimator is used to compare the difference 
between the two treatments in terms of the estimated AUCs. Finally, the proposed 
method will be applied to a simulated dataset to determine if there is significant 
difference between two treatments. Results: The statistical results show that the 
95% bootstrap percentile confidence interval (BPCI) is (-3.06, -3.59). Since the BPCI 
does not contain zero, we claim that the treated group (M= 1) is significantly differ-
ent from the control group (M= 0) at a 5% level in overall longitudinal multivariate 
health outcomes. ConClusions: In this paper, we propose a simple and efficient 
approach to overcome the difficulty of analyzing MLD in practice. We demonstrate 
how to use our proposed method with a simulated dataset. Our simulated data set 
allowed us to demonstrate how our proposed method may be particularly useful 
for analyzing longitudinal HRQoL assessments in medical studies.
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objeCtives: To assess medical and pharmacy students’ knowledge and perception 
about generic medicines and its quality and prices in Kabul- Afghanistan. Methods: 
A questionnaire based convenience sample of 255 was applied and study was con-
ducted at Kabul Medical University and Pharmacy Faculty of Kabul University. The 
questionnaire had 19 questions and was designed in two sections (definition of 
generic and branded medicine and perception towards generic medicine). A total 
of 95 pharmacy and 125 medical students had voluntarily participated in the sur-
vey. SPSS version 16 was used for data analysis purposes. Results: Among the 
total target n = 220 (response rate 86.27%) students voluntarily participated in the 
survey and n = 27 (28.42%) of the pharmacy students were working as pharmacists 
in the private pharmacy outlets. In reference to the knowledge about generic medi-
cines n = 173 (67.84%) of the respondents had knowledge about generic medicines. 
The interviewees n = 205 (80.39%) expressed that the quality is their major con-
cern, when buying generic medicines. Both groups have shown unanimity n= 216 
(84.70%) that prescription of generic medicines promotes cost containment among 
the patient. ConClusions: The current study emphasizes that awareness and 
knowledge about generic medicines by including special topics in the medical and 
pharmacy curriculum is important and further promoting culture of prescribing 
generic medicines in daily practice.
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objeCtives: Out of 200 of the most populous U.S. counties, Philadelphia has the 
fifth highest infant mortality rate. Keystone First partnered with Verizon Wireless 
to launch Moms2B—a program providing free cell phones and minutes to directly 
engage Keystone First’s high-risk pregnant Medicaid members. The goals are to 
improve prenatal care and health outcomes, and keep members connected to 
the plan’s Bright Start® maternity program. Methods: The Bright Start Care 
Management team contacted participants on the cell phones to provide coach-
ing and care coordination during pregnancy and postpartum. Participants also 
received text messages with nutritional and clinical information specific to gesta-
tional age. In addition, they received encouragement and gift incentives to main-
tain scheduled prenatal/postpartum care, along with information about screenings, 
and educational and community-based programs. Seventeen participants actively 
engaged in Moms2B (intervention group: IG) were risk-matched to 17 nonparticipat-
ing high-risk pregnant members (control group: CG). Matching variables included 
